Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.67 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.67 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503041 | 1.00 | TLR7 (0.67) | TLR7TLR8NUDT1KDM4EGLA | |
| SCHEMBL23332392 | 0.94 | TLR7 (0.64) | TLR7TLR8NUDT1 | |
| SCHEMBL14451806 | 0.94 | TLR7 (0.64) | TLR7TLR8NUDT1 | |
| SCHEMBL23332176 | 0.94 | TLR7 (0.64) | TLR7TLR8NUDT1 | |
| SCHEMBL25967029 | 0.94 | TLR7 (0.68) | TLR7TLR8NUDT1 | |
| SCHEMBL20756506 | 0.93 | TLR7 (0.70) | TLR7TLR8NUDT1 | |
| SCHEMBL10135793 | 0.93 | TLR7 (0.56) | TLR7TLR8NUDT1KDM4EGLA | |
| SCHEMBL23331696 | 0.92 | TLR7 (0.61) | TLR7TLR8NUDT1 | |
| SCHEMBL10267526 | 0.92 | TLR7 (0.54) | TLR7TLR8NUDT1KDM4EGLA | |
| SCHEMBL23331422 | 0.91 | TLR7 (0.61) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372500-A1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | NEKTAR THERAPEUTICS (US) | 2023-11-23 | — | — | US | disclosed |
| US-20210130467-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | NEKTAR THERAPEUTICS | 2021-05-06 | — | — | US | disclosed |
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034802-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034802-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-1667694-B1 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS INC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7576068-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576068-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576068-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1667694-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | Anadys Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005025583-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130467-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | CD274, TLR7, PDCD1LG2 | TLR7 2/4885TLR8 5/4885NUDT1 2779/4885 |
| US-20230372500-A1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885NUDT1 1567/4885 |
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | TLR7 1/4885TLR8 6/4885NUDT1 150/4885 |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | TLR7 1/4885TLR8 6/4885NUDT1 150/4885 |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | TLR7, TLR3, TLR9 | TLR7 1/4885TLR8 6/4885NUDT1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.